Phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E Mutant Metastatic NSCLC

Personalized therapy to further improve outcomes in Patients with BRAF Mutated mNSCLC

NSCLC is a heterogeneous set of diseases defined by oncogenic drivers

Twice daily tRT by IMRT compasred with SIB IRT with concurrent chemotherapy

Long term Survival & Competing Rsks of Death in the ESPATUE Randomized Phase III

Impact of radiation dose to the immune cells in unresectable or stage III

Outcomes of 1L immune checkpoint inhibitors with or without chemotherapy

Pembrolizumab versus best supportive care survival outcomes in ECOG performance

Effectiveness of PD L1 inhibitors alone or in combination with platinum doublet

Low dose & Alternate IO

Comparative Effectiveness and Safety of Standard Dose and Low Dose Pembrolizumab

Panel Discussion - Redefining the management of NSCLC with Atezolizumab

Vascular invasion in Stage I Lung adenocarcinoma Implications

A Systematic Review into the Radiologic Features Predicting Local Recurrence

Chest CT Scan+CXR versus CXR for follow up

Bevacizumab plus erlotinib versus erlotinib alone in Japenese patients

Furmonertinib versus gefitinib in treatment naive EGFR mutated non small cell lung cancer

7MO Oritinib a third generation EGFR tyrosine kinase inhibitor in locally advanced

Almost all the patients and caregivers want Lung Connect to continue

Welcome & Introduction

What are the needs of Lung Cancer patients & caregiver

NOVEL APPROCHES UPDATES AND PERSPECTIVE FOR LUNG CANCER NURSING

Promoting Early Diagnosis of Lung Cancer

Challenges in Diagnosis and Treatment of Lung Cancer

Recent Developments on Molecular Diagnosis of Lung Cancer

Current Practice and Emerging Breakthroughs in AI Imaging Radiomics in Lung Cancer

Image Guided Tissue Sampling